RxSight Outlines Strategic Priorities and Next-Generation Lens Timeline
During the Q3 2026 earnings call, RxSight CEO Aziz Mottiwala outlined a strategic roadmap focused on three core pillars: strengthening the U.S. Light Adjustable Lens (LAL) business, advancing the next-generation adjustable lens pipeline, and capitalizing on the partnership with Alcon. The company provided updated timelines for its product development, noting that the earliest arrival for its next-generation LAL technology is projected for 2028. Management also indicated plans to resume providing financial guidance for 2027 as they execute these long-term growth initiatives.
Topics: corporate partnership product pipeline Q3 earnings strategic priorities
Read the full article at Seeking Alpha
Part of the story RxSight outlines 2028 earliest next-gen LAL timing as it plans to resume 2027 guidance (2 articles)